InterMune's Esbriet faces delays for EU reimbursement and ASCEND study in US
This article was originally published in Scrip
Executive Summary
Despite delays in gaining reimbursement for Esbriet (pirfenidone) in Europe and starting a Phase III clinical trial necessary for US FDA approval of the idiopathic pulmonary fibrosis (IPF) drug, investors sent InterMune 's stock price higher on news regarding French National Health Insurance coverage.